BioSpace News Archive

Business

Cologuard® revenue increased 63 percent to $118 million, and Cologuard test volume grew 49 percent to 241,000 during third quarter

Exact Sciences Corp. today announced that the company generated revenue of $118.3 million

October 30, 2018
·
9 min read
BioMidwest

Hill-Rom to Present at the Stifel 2018 Healthcare Conference

Hill-Rom Holdings, Inc. will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018, in New York. John Groetelaars, Hill-Rom’s president and chief executive officer, is scheduled to present at 8:00 a.m. Eastern Time.

October 30, 2018
·
1 min read
Business

NuVasive Reports Third Quarter 2018 Financial Results

NuVasive, Inc. today announced financial results for the quarter ended September 30, 2018.

October 30, 2018
·
32 min read
Business

Accuray Reports Fiscal 2019 First Quarter Financial Results

Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2019 ended September 30, 2018.

October 30, 2018
·
12 min read
Business

Pulse Biosciences Quarterly Ended September 30, 2018 Investor Conference Call

Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT

October 30, 2018
·
8 min read
Pharm Country

U.S. Pharmaceutical Companies Have Moved Vaccine Sales Forces Toward a More Specialized Approach, According to PharmaForce International

Data from PharmaForce International’s Deployment Analyzer indicates that U.S. pharmaceutical companies focusing on vaccine deployment have moved their sales forces toward a more specialized approach.

October 30, 2018
·
2 min read
Biotech Beach

Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling

The newest addition to the Illumina oncology portfolio offers researchers the ability to measure Tumor Mutational Burden and Microsatellite Instability, and detect other known and emerging biomarkers

October 30, 2018
·
6 min read
FDA

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Approval Based on Results of Phase 3 KEYNOTE-407 Trial, Which Demonstrated Superior Overall Survival with KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone

October 30, 2018
·
30 min read
Business

Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018

-- Conference Call Scheduled for Thursday, November 8, 2018 at 4:30 p.m. EDT --

October 30, 2018
·
2 min read
Job Trends

Ageless Forever Offers CoolSculpting In Las Vegas, NV To Freeze Away Body Fat

Ageless Forever’s CoolSculpting clinic in Las Vegas is changing the way people get rid of unwanted body fat by utilizing advanced medical technology to freeze the fat away.

October 30, 2018
·
2 min read